1 Start 2 Preview Answers 3 Complete Please complete the following pre-survey before attending the 2023 Women's Masterclass meeting. First and Last Name * Email * Studies have shown that women have a(n) _________ risk of developing statin intolerance compared to men. * Higher Lower Equal Which of the following is TRUE about women and ASCVD risk? * Women are more likely to fill a high statin prescription vs. men Lipid lowering therapies are less effective in women vs. men ASCVD is recognized 10 years later on average in women vs. men of same age Men have a higher prevalence and burden of ASCVD vs. women All of the following non-statin therapies have shown no difference or improved outcomes in women, EXCEPT: * PCSK9 inhibitors Ezetimibe Fibrates Bempedoic acid Niacin Icosapent ethyl According to the 2022 ACC Expert Consensus Decision Pathway on Non-Statin Therapies, which of the following is an appropriate LDL-C target in a woman with ASCVD, type 2 diabetes and hypertension? * ≥50% LDL-C reduction AND LDL-C <55 mg/dL ≥50% LDL-C reduction OR LDL-C <55 mg/dL ≥50% LDL-C reduction AND LDL-C <70 mg/dL ≥50% LDL-C reduction OR LDL-C <70 mg/dL ≥50% LDL-C reduction AND LDL-C <100 mg/dL ≥50% LDL-C reduction OR LDL-C <100 mg/dL Which of the following statements is TRUE about the CLEAR Outcomes trial with bempedoic acid? * It enrolled patients with existing ASCVD It enrolled patients at-risk for or with existing ASCVD Significant cardiovascular risk reduction was observed in the primary prevention cohort only It enrolled patients on high-intensity statin therapy A 58-year-old female with family history of ASCVD but without a history of an ASCVD event, presents for follow-up. She has experieced adverse events with both atorvastatin and rosuvastatin, and has discontinued statins altogether. Her medical history is relevant for obesity, type 2 diabetes, and hypertension, and her current LDL-C is 110 mg/dL. Which of the following would be most beneficial to help reduce her ASCVD risk? * Bempedoic acid Colchicine Empagliflozin Simvastatin Niacin A 58-year-old woman with a recent myocardial infarction and stent placement to the LAD 6 months ago has been tried multiple statins and has severe myalgias with high intensity and moderate intensity statins. The patient is on a maximally tolerated dose of statin (pravastatin 20 mg daily). Ezetimibe 10 mg is then added and lipid profile reveals: total cholesterol = 261 mg/dL; triglycerides = 150 mg/dL ; HDL = 40 mg/dL; LDL-C = 175 mg/dL; LP(a) = 200 mg/dL. According to the 2022 ACC Expert Decision Pathway on non-statin therapies, which of the following options should you consider next to reduce the risk of future cardiovascular events? * Add a PCSK9 inhibitor Add inclisiran Add icosapent ethyl Add niacin Add bempedoic acid True or False: according to the 2022 ACC consensus statement on non-statin therapies for LDL-C lowering, inclisiran and a PCSK9 inhibitor can be reasonably combined together in very high-risk patients that need further LDL-C lowering. * True False Please share 3-5 personal learning objectives and what you anticipate learning from the attending the Women’s Cardiometabolic Health and Wellness MasterClass. * Leave this field blank
